SCHEDULE: Vanguard Group Discloses 4.39% Stake in Actinium Pharmaceuticals

The Vanguard Group has reported a 4.39% beneficial ownership stake in Actinium Pharmaceuticals Inc., holding 1,371,840 shares of common stock.

Summary

• The Vanguard Group holds 1,371,840 shares of Actinium Pharmaceuticals Inc. common stock.
• This ownership represents 4.39% of the total class of securities.
• Vanguard maintains sole dispositive power over 1,362,947 shares and shared dispositive power over 8,893 shares.
• Vanguard holds no sole or shared voting power over these shares.
• The filing is an Amendment No. 1 to a Schedule 13G, filed under Rule 13d-1(b), indicating the shares were acquired and are held in the ordinary course of business without the purpose of changing or influencing control of the issuer.

Sentiment

Score: 5

Explanation: The filing is a routine beneficial ownership disclosure by an institutional investor, indicating a passive stake below the 5% threshold for more active reporting (13D), and does not contain information to suggest a positive or negative sentiment regarding the company's performance or outlook.

Future Outlook

NA

Industry Context

This filing is a routine disclosure of an institutional investor's passive stake in a biotechnology company. It does not provide specific industry context beyond the fact that a major asset manager holds shares in a pharmaceutical firm.

Stakeholder Impact

• Shareholders are informed of a significant institutional investor's passive stake in the company, which may be viewed as a vote of confidence.

Key Dates

Keywords

Actinium Pharmaceuticals, Vanguard Group, Beneficial Ownership, Schedule 13G, Common Stock, Institutional Investor